Galleri is the multi-cancer early detection test developed by GRAIL.
1 report, 1 independent
Updated Jul 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Galleri is the multi-cancer early detection test developed by GRAIL.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
GRAIL
American biotechnology and pharmaceutical company
Related events
- A key meeting was held to review the Galleri blood test developed by GRAIL.
- The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.
- GRAIL utilizes a central laboratory in North Carolina and leverages Quest locations for blood sample collection for its multi-cancer early detection test.
- Grail is conducting trials with the NHS, seeking FDA approval for its Galleri test, and presenting data at ASCO.
Coverage
Newest first; wire copies grouped- Insider MonkeyGRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA Submission GRAIL Inc. (NASDAQ:GRAL) is one of the best young stocks to buy and hold for 5 years. On